Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nonpegylated liposomal doxorubicin + paclitaxel + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Teva Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of non-pegylated liposomal doxorubicin (NPLD), paclitaxel, and trastuzumab. NPLD is a liposomal formulation of doxorubicin that provides similar anti-tumor efficacy with significantly reduced cardiotoxicity compared to conventional doxorubicin. Paclitaxel is a taxane chemotherapy agent. Trastuzumab is a monoclonal antibody that targets HER2-positive cancer cells. This combination is likely used for HER2-positive breast cancer, particularly in metastatic settings, providing both cytotoxic effects and targeted HER2 inhibition with a potentially improved cardiac safety profile.
- Brand names
- Myocet
- Other names
- nonpegylated liposomal doxorubicin + paclitaxel + trastuzumabNPLD + paclitaxel + trastuzumabMTP regimen
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on nonpegylated liposomal doxorubicin + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nonpegylated liposomal doxorubicin + paclitaxel + trastuzumab.